Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 19/05/17 at 09:46am

With every week we draw closer to the event everyone in the UK is talking about - the general election. While it is dominating the headlines and will continue to do so until the 8 June vote, a different set of stories piqued the interest of our readers this week.

New FDA Commissioner Scott Gottlieb has seen his first week on the job, and has wasted no time in commanding a significant restructure to the regulator's workforce. Additionally, J&J have been warned by the organisation over the risk of amputation posed bu its diabetes medication Invokana. But Brexit is once again the topic of the week, with our medical comms feature on the threat of talent drain winning out as our most-read story.

10. China threatens prison time and death penalty to fight fraudulent trial data

In a drastic move to help solve its notorious problem with fraudulent clinical trial data, China has introduced a policy shift in its criminal code meaning that persons wilfully submitting fake data will be imprisoned or even executed.

9. Common treatment for MS revealed to have potential adverse reactions

A study by the University of British Columbia ascertained whether the widely used treatment, beta interferons, had any potentially adverse side-effects.

8. Novartis signs drug access deal with Pakistan government

Pakistan’s Ministry of National Health Services, Regulations and Coordination has signed an agreement with Novartis to improve access to medicines for chronic disease.

7. Lilly’s migraine drug succeeds in Phase 3 trials

Eli Lilly announced the successful results of three Phase 3 trials examining the benefits of its drug, galcanezumab, in patients with episodic and chronic migraines, finding that it improved the number of days without migraines.

6. FDA demands new warnings for J&J diabetes drug over amputation risk

The FDA is requiring J&J to add new precautionary labelling to its diabetes treatment Invokana (canagliflozin), warning users of the risk of foot and leg amputations.

5. Cuba looks to begin trials of new neuroprotective treatment for Alzheimer’s

When Cuba announces a new innovation in medicine, it carries more significance than any other nation of relative size and so it has captured interest by announcing it will begin a new trial into a neuroprotective medicine for Alzheimer's.

4. AZ launches lawsuit against former executive for defecting to GSK

AstraZeneca has launched a lawsuit against former Executive Vice President for Europe Luke Miels after he jumped ship to join rival pharma giant GlaxoSmithKline as President of Global Pharmaceuticals.

3. New FDA Commissioner Gottlieb restructures workforce with product-based focus areas

The new FDA head has called for a reorganisation of its 4,000 inspection staff which will see them working in one of six focused areas, as opposed to the broad approach which was taken previously.

2. GSK mulls $8 billion healthcare consolidation deal

GSK is deciding whether it wants to double down on its healthcare investment by offering to take the entire business off Novartis’ hands.

1. Brain drain: The experts the UK may lose due to Brexit

The regulatory and drug approval process is destined to change once the UK leaves the EU. The problem is, nobody is quite sure how things will change and how they should react in turn.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providi